Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 6
Submit an article Journal homepage
619
Views
23
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

Xing-Nong YeInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and ;Department of Hematology, The fourth Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China
,
Xin-Ping ZhouInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and
,
Ju-Ying WeiInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and
,
Gai-Xiang XuInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,
,
Ying LiInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,
,
Li-Ping MaoInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,
,
Jian HuangInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;Department of Hematology, The fourth Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China
,
Yan-Ling RenInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and
,
Chen MeiInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and
,
Jing-Han WangInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,
,
Yin-Jun LouInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,
,
Li-Ya MaInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,
,
Wen-Juan YuInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,
,
Li YeInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and
,
Li-Li XieInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and
,
Yin-Wan LuoInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and
,
Chao HuInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and
,
Lin-Mei NiuInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and
,
Min-Hua DouInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and
,
Jie JinInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,
&
Hong-Yan TongInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and Correspondence[email protected]
 show all
Pages 1311-1318 | Received 05 Feb 2015, Accepted 03 Sep 2015, Published online: 13 Oct 2015

References

  • Nimer SD. Myelodysplastic syndrome. Blood 2008; 111: 4841–4851.
  • Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 2007; 13: 4225–4232.
  • Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma 2013; 54: 2003–2007.
  • Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803.
  • Yang AS, Doshi KD, Choi SW, et al. DNA methylation changes after 5-aza-2’-deoxycytidine therapy in patients with leukemia. Cancer Res 2006; 66: 5495–5503.
  • Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635–1640.
  • Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010; 107: 7473–7478.
  • Song LX, Xu L, Li X, et al. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia. Ann Hematol 2012; 91: 1879–1886.
  • Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 2011; 118: 1472–1480.
  • Li K, Hu C, Mei C, et al. Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target. J Transl Med 2014; 12: 167.
  • Greenberg PL, Attar E, Bennett JM, et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw 2011; 9: 30–56.
  • Germing U, Kobbe G, Haas R, et al. Myelodysplastic syndromes: diagnosis, prognosis, and treatment. Dtsch Arztebl Int 2013; 110: 783–790.
  • Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336.
  • Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075–4083.
  • Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998; 92: 2322–2333.
  • Issa JP, Baylin SB, Herman JG. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 1997; 11: S7–S11.
  • Melki JR, Clark SJ. DNA methylation changes in leukaemia. Semin Cancer Biol 2002; 12: 347–357.
  • Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108: 3271–3279.
  • Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66: 6361–6369.
  • Blum W, Schwind S, Tarighat SS, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 2012; 119: 6025–6031.
  • Willemze R, Archimbaud E, Muus P. Preliminary results with 5-aza-2’-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. Leukemia 1993; 7: 49–50.
  • Willemze R, Suciu S, Archimbaud E, et al. A randomized phase II study on the effects of 5-Aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia 1997; 11: S24–S27.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.